GlaxoSmithKline, Respiratory Therapy Area, Gunnels Wood Road, Stevenage, UK.
Novartis Pharma AG, Basel, Switzerland.
Drug Discov Today. 2018 Sep;23(9):1622-1634. doi: 10.1016/j.drudis.2018.06.015. Epub 2018 Jun 21.
Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) was initiated in the first year of the Innovative Medicines Initiative (IMI). It was an ambitious plan to tackle the understanding of asthma through an integration of clinical and multi-'omics approaches that necessitated the bringing together of industry, academic, and patient representatives because it was too large to be managed by any one of the partners in isolation. It was a novel experience for all concerned. In this review, we describe the main features of the U-BIOPRED experience from the industry perspective. We list some of the key advantages and learnings from the perspective of the authors, and also improvements that we feel could be made in future projects.
“用于预测呼吸疾病结局的无偏生物标志物（U-BIOPRED）”项目于创新药物倡议（IMI）的第一年启动。该项目雄心勃勃，计划通过整合临床和多组学方法来深入了解哮喘，这需要将工业界、学术界和患者代表聚集在一起，因为单凭任何一个合作伙伴都无法独立管理如此庞大的项目。这对所有相关方来说都是一次全新的体验。在这篇综述中，我们从工业界的角度描述了 U-BIOPRED 项目的主要特点。我们从作者的角度列出了一些关键的优势和经验教训，并提出了我们认为未来项目可以改进的地方。
